NanoImaging Services (NIS) is a leading company in cryo-electron microscopy (cryo-EM) for drug discovery, specializing in gene-to-structure, structural biology, and nanoparticle characterization using Glacios & Krios technologies. NIS, founded in 2007, has established itself as an industry pioneer with the most extensive cryo-EM expertise and resources in North America, including a team of cryo-EM scientists and TEM microscopes.
The company's focus on structural biology encompasses high-resolution data collection and single-particle analysis, enabling structure-based drug design with an impressive average sample-to-structure turnaround time of only 4 weeks. Additionally, NIS offers comprehensive nanoparticle characterization, providing morphology assessment for size, shape, uniformity, purity, and cargo encapsulation, with R&D and GMP-compliant services available.
Through its cutting-edge technology and extensive knowledge, NIS aims to democratize access to cryo-EM for companies at every stage of the drug discovery pipeline, expediting the development of innovative therapeutics. The company received a Private Equity Round investment on 12 June 2023 from Ampersand Capital Partners.
NIS operates in the Biotechnology and Pharmaceutical industries and is headquartered in the United States. With its pivotal role in advancing cryo-EM applications in drug development, NIS stands at the forefront of pioneering technologies that have the potential to revolutionize the pharmaceutical landscape.
No recent news or press coverage available for NanoImaging Services.